ArticleHepatic oncology2014
The biological and clinical challenge of liver cancer heterogeneity.
Article in Hepatic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Lineage and ecology define liver tumor evolution in response to treatment.Cell reports. Medicine · 2024Article
- Location matters: cellular heterogeneity in the hepatic lobule and hepatocellular carcinoma.American journal of physiology. Gastrointestinal and liver physiology · 2023Article
- Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer.Nature communications · 2022Article
- Ultrasomics prediction for cytokeratin 19 expression in hepatocellular carcinoma: A multicenter study.Frontiers in oncology · 2022Article
- Overcoming biological barriers to improve solid tumor immunotherapy.Drug delivery and translational research · 2021Review
- Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2021Review
- Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Journal of hepatology · 2021Article
- Electromagnetic Tracking and Optical Molecular Imaging Guidance for Liver Biopsy and Point-of-Care Tissue Assessment in Phantom and Woodchuck Hepatocellular Carcinoma.Cardiovascular and interventional radiology · 2021Article
- Loss of ARID1A Promotes Hepatocellular Carcinoma Progression via Up-regulation of MYC Transcription.Journal of clinical and translational hepatology · 2021Article
- Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.Bioscience reports · 2021Article
- Article
- CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype.Journal of Cancer · 2020Review
- Observational
- Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.Cancers · 2019Review
- Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAMCancer research · 2019Article
- Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.Hepatology (Baltimore, Md.) · 2019Review
- Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization.International journal of biological sciences · 2019Article
- The significance of intertumor and intratumor heterogeneity in liver cancer.Experimental & molecular medicine · 2018Review
- Systemic treatments for hepatocellular carcinoma: challenges and future perspectives.Hepatic oncology · 2018Review
- Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.Cancer cell · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.